Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BGE-105
Azelaprag · 1 trial · 1 indication
Assessment of PK parameter, area under the curve (AUC) from time 0 to time of the last observed serum concentration (AUC0-t)
Assessment of PK parameter, area under the curve (AUC) over the dosing interval from time 0 to 24 hours following the final dose (AUC0-24)
Assessment of PK parameter, UAC from time 0 to infinity (AUC0-inf)
Assessment of PK parameter, maximum observed serum concentration (Cmax)
Assessment of PK parameter, time to reach Cmax (Tmax)
Assessment of PK parameter, terminal elimination half-life (T1/2)
Assessment of PK parameter, Total body clearance (CL)
Assessment of PK parameter, volume of distribution (Vz)
| Arm | Type | Description |
|---|---|---|
| Single dose, 2-way crossover in Part 1, then daily dosing for 14 days in Part 2 | EXPERIMENTAL | Study Part 1: Participants will receive a single Dose A or B on Day 1 and then followed by a crossover to a single Dose B or A on Day 8. Study Part 2: Participants in Study Part 2 will receive either a single Dose C or equivalent of Dose C administered twice daily, starting on Day 1 and through Day 14 |
| Name | Type | Description |
|---|---|---|
| Azelaprag | DRUG | oral, apelin receptor (APJ) agonist |
Key Inclusion Criteria: Patients who meet ALL the following inclusion criteria will be eligible to participate in the study: 1. Healthy male or female volunteers ≥ 60 years of age 2. No history or evidence of clinically relevant medical disorders 3. Body mass index (BMI) between 18 and 40 kg/m2 4....
Azelaprag is an investigational small molecule developed by BioAge Labs, Inc. (ticker BIOA). It is in Phase 1 clinical development and has been studied in healthy older adult volunteers. Its therapeutic indications have not been disclosed.
Azelaprag is being developed by BioAge Labs, Inc., which trades under the ticker BIOA. The company has completed a Phase 1 pharmacokinetics study of the drug in older adult healthy volunteers.
Azelaprag is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA.
Azelaprag has been evaluated in one completed Phase 1 trial, NCT06141889, titled Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers. The trial enrolled 16 participants aged 60 years and older in New Zealand.
Yes, Azelaprag is also known as BGE-105. The completed Phase 1 pharmacokinetics trial is listed under the name Azelaprag (BGE-105), so both names refer to the same investigational small molecule developed by BioAge Labs, Inc.